8 results about "Serotype a" patented technology

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

Provided herein are solid compositions comprising Clostridium botulinum neurotoxin serotype A (BoNT / A), human serum albumin (HSA) and sodium chloride (NaCl); wherein less than 34% of soluble HSA conta

A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca

The present invention belongs to the field of chemistry. Disclosed in the present invention is a method for the chemical synthesis of a Vibrio vulnificus biotype 2 serotype A O-antigen disaccharide fragment. In the present invention, D-glucose, L-galactose, etc. are used as raw materials to prepare two glycosylated building blocks, and a set of synthesis routes for efficiently constructing a disaccharide fragment is designed. By means of the optimization of a protecting group and the timing for introducing a modification group, the target disaccharide is successfully prepared. The disaccharide prepared in the present invention has easily obtainable raw materials, and a simple and easily repeatable preparation method, and has good application prospects in the aspects such as the development of new drugs and vaccines for Vibrio vulnificus.

Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a 150 kDa BoNT / A. Said 150 kDa BoNT / A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT / A sequence variant species with a C-terminal truncated light chain.

Provided herein are Haemophilus influenzae saccharide-carrier conjugates and compositions thereof. Also provided are methods of making and using the conjugates and compositions thereof, and kits containing the conjugates. Haemophilus influenzae saccharide-lipid conjugates, Haemophilus influenzae saccharide-glycosphingolipid conjugates, compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed. Saccharide-lipid conjugates, and saccharide-glycosphingolipid conjugates comprising saccharides from Haemophilus influenzae serotype a, as well as compositions containing these, methods of making and using the conjugates and compositions, and kits containing these, are also disclosed.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.